查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球幹細胞庫市場
市場調查報告書
商品編碼
1153816

2022-2029 年全球幹細胞庫市場

Global Stem Cell Banking Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

全球幹細胞銀行市場在 2021 年將達到 50.1563 億美元，到 2029 年將達到 159.4792 億美元，在預測期內 (2022-2029) 的複合年增長率為 15.68%，預計將在

幹細胞是未分化的細胞，可以通過細胞分裂無限地自我更新。此外，這些細胞可以分化成具有特定功能的更成熟的細胞。幹細胞現在用於治療 80 多種令人頭疼的疾病。幹細胞庫收集、提取和冷凍保存幹細胞和其他免疫系統細胞，以供未來潛在的醫療用途。

市場動態

人們對乾細胞治療潛力的認識不斷提高，這推動了對這些診斷產品的需求不斷增加。此外，新技術的進步和研發費用的增加也是推動市場增長的因素。所有這些因素都有望推動市場增長。

越來越多的新產品發布和不斷增加的研發將推動市場增長。

幹細胞庫的全球市場主要是由人們對乾細胞治療潛力的認識不斷提高所推動的。推動市場增長的其他因素包括新型乾細胞儲存、加工和保存技術的進步。增加造血幹細胞移植和增加對基於乾細胞的研究的投資將進一步推動干細胞庫。新興經濟體、全球主要疾病負擔的增加、高出生率、GDP 增長和可支配收入的增長為主要參與者提供了市場機會。例如，2021 年 9 月，幹細胞庫和診斷解決方案提供商 LifeCell 宣布其新療法 Mesocel 將獲得印度 DGCI（藥物管制總局）治療 COVID-19 的臨床試驗批准。宣布已收購Mesocel 來源於從捐贈的臍帶組織中獲得的間充質乾細胞。這使得能夠治療患有危及生命的 COVID-19 肺炎和急性呼吸窘迫的患者。臨床試驗將分兩個階段進行。

越來越多的融資輪次、新技術進步和最新的創新產品發布導致對這些幹細胞庫的高需求。例如，2021 年 3 月，幹細胞銀行 LifeCell 推出了 StemMatch，這是銀行會員社區的首創服務，可提供有關可在 LifeCell 註冊表中匹配的干細胞單位的確切質量和數量的信息。

幹細胞庫的高處理和運營成本阻礙了市場增長。

然而，幹細胞庫的高運營成本、幹細胞採集過程中的法律和倫理問題、嚴格的監管框架以及低接受度和認可度可能會阻礙市場的進步。這些幹細胞療法的高成本阻礙了市場增長。據幹細胞治療創新診所 DVC Stem 稱，其 IRB 批准的間充質乾細胞 (MSC) 方案預計成本約為 25,000 美元。

COVID-19 影響分析

疫情對全球金融預期、運營和危機應對策略產生了負面影響。 COVID-19 疫情對醫療保健行業產生了嚴重影響。由於 COVID 的關注，所有研究和臨床試驗都受到影響，幹細胞銀行市場遭受了巨大損失。但現在，市場進入者正在改變他們的長期和短期增長戰略，利用研究市場和創造尖端項目來對抗這一流行病。世界各地正在發生各種倡議、合作和合併，促進了市場的增長。例如，2022 年 8 月，臍帶血再生療法製造商 StemCyte 宣布獲得美國食品和藥物管理局的批准，可以使用臍帶血幹細胞療法對 COVID 後綜合徵進行 2 期臨床試驗。

內容

第 1 章市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 新產品發布次數增加
      • 增加研發
    • 約束因素
      • 與乾細胞療法相關的高費用
    • 商機
    • 影響分析

第五章行業分析

  • 搬運工的五種力量
  • 未滿足的需求
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章出處

  • 臍帶來源的干細胞 (UCSC)
  • 胎盤幹細胞 (PSC)
  • 脂肪組織來源的干細胞 (ADSC)
  • 骨髓來源的干細胞 (BMSC)
  • 人類胚胎幹細胞 (HESC)
  • 其他幹細胞來源

第 8 章按服務類型

  • 保存/儲存
  • 處理中
  • 收集和運輸
  • 分析

第9章銀行類型

  • 公共機構
  • 私人

第 10 章應用

  • 腦癱
  • 白血病
  • 地中海貧血
  • 糖尿病
  • 自閉症
  • 其他

第11章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第12章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 值得關注的主要公司名單

第13章公司簡介

  • Stem Cyte, Inc.
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Cryo-cell International
  • American CryoStem Corporation
  • ViaCord
  • Cord Blood Registry Systems
  • SmartCells, Inc.（Merck）
  • LifeCell International Pvt. Ltd.
  • Cryoviva Biotech Pvt. Ltd
  • Cordlife Group Ltd.
  • Transcell Biolife Pvt. Ltd.

第14章 全球幹細胞庫市場-DataM

簡介目錄
Product Code: DMBT860

Market Overview

The global stem cell banking market was valued at US$ 5,015.63 million in 2021 and is estimated to reach US$ 15,947.92 million by 2029, growing at a CAGR of 15.68% during the forecast period (2022-2029).

Stem cells are undifferentiated cells that can self-renew indefinitely through cell division. These cells can also be distinguished into more mature cells with specific functions. Currently, stem cells are used to treat more than 80 nasty diseases. Stem cell banking is collecting, extracting and storing by cryogenically freezing the stem cells and other immune system cells for potential future medical use.

Market Dynamics

The increasing demand for these diagnostic products is due to the growing awareness of the therapeutic potential of stem cells. Other factors aiding the market growth are the advancements in novel technologies and increasing research and development expenditure. All these factors are expected to drive market growth.

The increasing number of novel product launches and the rising research and development will drive market growth.

The global market for stem cell banking is primarily driven by the growing awareness of the therapeutic potential of stem cells. Other factors aiding the market growth are advancements in novel stem cell preservation, processing, and storage technologies. The rise in hematopoietic stem cell transplantation procedures and increasing investments in stem cell-based research further propel stem cell banking. Emerging countries, the rising global burden of major diseases, the large number of newborns, the growth in GDP growth, and disposable income act as market opportunities for key players. For instance, in Sep 2021, LifeCell, a stem cell bank and provider of diagnostic solutions, announced that its novel therapy, Mesocel, got approved for a clinical trial from DGCI, the Drug Controller General of India, for COVID-19 treatment. Mesocel is extracted from mesenchymal stem cells derived from the donated umbilical cord tissue. This can now be used to treat patients with life-threatening COVID-19 pneumonia or acute respiratory distress. The clinical trial will be conducted in 2 phases.

Various funding, novel technological advancements, and the number of the latest, innovative product launches are increasing, leading to the high demand for these stem cell banking. For instance, in Mar 2021, LifeCell, a stem cell banking company, launched StemMatch, a first-of-its-kind service for the banking members community as it gives information on the accurate quality and number of stem cell units that are matching available within the LifeCell registry.

The high therapy and operational costs associated with stem cell banking will hamper the market's growth.

However, the high operational costs of stem cell banking and legal and ethical issues during the collection of stem cells, along with stringent regulatory frameworks and lack of acceptance and awareness, may hinder the market progress. The high cost of these stem cell therapies is hindering the market growth. According to DVC Stem, an innovative clinic of stem cell therapy, its mesenchymal stem cell (MSC) protocol that is IRB approved costs around US$25,000.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The stem cell banking market has experienced huge losses due to COVID, as all the research and clinical trials got affected due to the diversion of attention toward COVID. But now, the market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Various initiatives, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in Aug 2022, StemCyte, a company manufacturing cord blood regenerative therapeutic, announced that Post-COVID Syndrome's Phase II clinical trial with the help of umbilical cord blood stem cell therapy got approved by U.S. Food and Drug Administration.

Segment Analysis

The umbilical cord-derived stem cells segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The umbilical cord-derived stem cells (UCSTs) segment is the highest market holder in the global stem cell banking market. Cord Blood is affluent in stem cells. Stem cells are developed in the bone marrow and differentiate into different blood cells, which are important in various therapies related to blood disorders, such as sickle cell disease. Umbilical cord blood can be used for gene therapy or transplantation as it's a hematopoietic stem cell source. Umbilical cord-derived mesenchymal stem cells can be used for inflammatory and immune disease therapy. These can be promising active substances for therapeutic product development as they have a few issues related to safety, availability and ethics.

Umbilical cord-derived stem cells dominate the market due to the rising birth rate and global chronic disease cases. According to the Centre for Disease Control and Prevention, in 2021, approximately 3,659,289 newborn cases were reported in the United States. The rising number of people suffering from blood-related disorders, regulatory approvals and growing technological advancements or research/clinical trial studies drive the market's growth. For instance, in May 2021, Cordlife Group Limited, 1st private cord blood bank in Singapore, entered into a partnership with SingHealth Duke-NUS Academic Medical Centre to test new technology that can increase blood-forming stem cells in number from stored umbilical cord blood that is stored in the first-in-man study in Singapore.

Geographical Analysis

North America holds the largest market share of the global stem cell banking market.

North America dominates the global stem cell banking market, primarily attributed to the rising prevalence of chronic ailments such as leukemia, thalassemia, diabetes, autism and many more due to changing environments worldwide, established healthcare infrastructure, and higher investment in R&D activities contribute to North America's rapid share growth. Moreover, its broad base patient population also contributes to the growth of its share. According to the American Cancer Society, in 2022, Around 60.650 estimated novel leukemia cases will occur, out of which 24,000 deaths will occur in the United States.

Moreover, the growing number of product launches is responsible for the market's growth. Other factors, such as the high spending of GDP on healthcare, stimulate the market's growth. Many key developments, technological advancements, collaborations and agreements are taking place in this region. For instance, in Feb 2021, American CryoStem Corporation, a biotechnology company at the clinical stage working on autologous cellular therapies, announced its agreement with BioTherapeutics Labs Corp., a company manufacturing umbilical cord tissues that's also FDA-registered.

Competitive Landscape

The stem cell banking market is highly competitive with local and global companies' presence. Stem Cyte Inc., Cryo-cell International, American CryoStem Corporation, ViaCord, Cord Blood Registry Systems, SmartCells, Inc. (Merck), LifeCell International Pvt. Ltd., Cryoviva Biotech Pvt. Ltd, Cordlife Group Ltd., Transcell Biolife Pvt. Ltd and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in Feb 2021, Cryo-Cell International Inc, a private cord blood bank that separates and stores stem cells, announced a collaboration with Duke University. With this agreement, Cryo-Cell gets the rights to regulatory data and proprietary processes developed at Duke related to cord tissue or blood.

StemCyte:

Overview:

StemCyte Inc. is a company involved in blood regenerative therapeutics. It provides family storage and public donations and is the only for-profit company that the US Department of HHS contracts. It was established in 1997 and is headquartered in California, United States.

Product Portfolio:

MaxCell: MaxCell is StemCyte's proprietary processing method that retains the stem cells in higher volume. It preserves more total nucleated cells than other standard processing procedures, improving engraftment chances.

Key Development: In May 2022, StemCyte, a blood regenerative therapeutics company, announced renewing its agreement with California Umbilical Cord Blood Collection Program. StemCyte helped raise collections at hospitals in Southern California by extending the cord blood collection hours.

The global stem cell banking market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising novel product launches
      • 4.1.1.2. Increasing research and development
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost associated with stem cell therapies
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply chain Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Source

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 7.1.2. Market Attractiveness Index, By Source
  • 7.2. Umbilical Cord-Derived Stem Cells (UCSCs)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Placental Stem Cells (PSCs)
  • 7.4. Adipose Tissue-Derived Stem Cells (ADSCs)
  • 7.5. Bone Marrow-Derived Stem Cells (BMSCs)
  • 7.6. Human Embryo-Derived Stem Cells (HESCs)
  • 7.7. Other Stem Cell Sources

8. By Service Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 8.1.2. Market Attractiveness Index, By Service Type
  • 8.2. Preservation and Storage*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Processing
  • 8.4. Collection and Transportation
  • 8.5. Analysis

9. By Type of Banking

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Banking
    • 9.1.2. Market Attractiveness Index, By Type of Banking
  • 9.2. Public *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Private

10. By Application

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Application
    • 10.1.2. Market Attractiveness Index, By Application
  • 10.2. Cerebral Palsy *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Leukemia
  • 10.4. Thalassemia
  • 10.5. Diabetes
  • 10.6. Autism
  • 10.7. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Banking
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Application
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Banking
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Application
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. The U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Banking
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Application
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Banking
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Application
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Banking
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), Application
    • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Stem Cyte, Inc.
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Cryo-cell International
  • 13.3. American CryoStem Corporation
  • 13.4. ViaCord
  • 13.5. Cord Blood Registry Systems
  • 13.6. SmartCells, Inc. (Merck)
  • 13.7. LifeCell International Pvt. Ltd.
  • 13.8. Cryoviva Biotech Pvt. Ltd
  • 13.9. Cordlife Group Ltd.
  • 13.10. Transcell Biolife Pvt. Ltd.

LIST NOT EXHAUSTIVE

14. Global Stem Cell Banking Market- DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us